TL;DR: Cigna Healthcare reaffirmed and modified MM 0372 for oral cancer screening systems, effective September 26, 2025. Every adjunctive oral cancer screening tool — including systems billed under CPT 41599 — remains non-covered as experimental and investigational. Here's what billing teams need to do.
If your practice offers VELscope, ViziLite, or any similar adjunctive oral screening technology, stop billing Cigna for it. The Cigna oral cancer screening systems coverage policy under MM 0372 has not opened a path to reimbursement — it has slammed the door and restated the position clearly. This update matters because practices that continue submitting CPT 41599 for these services will see claim denial with no viable appeal pathway based on medical necessity.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Oral Cancer Screening Systems |
| Policy Code | MM 0372 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium — affects oral surgery, dentistry-adjacent billing, ENT, and head/neck oncology practices billing adjunctive screening services to Cigna |
| Specialties Affected | Oral surgery, otolaryngology (ENT), head and neck oncology, general dentistry practices with medical billing |
| Key Action | Remove CPT 41599 for adjunctive oral cancer screening from your Cigna charge capture immediately — these claims will not be reimbursed |
Cigna Oral Cancer Screening Coverage Criteria and Medical Necessity Requirements 2025
The Cigna oral cancer screening systems coverage policy is unambiguous. Cigna Healthcare does not consider adjunctive oral cancer screening systems — including fluorescence-based and chemiluminescence-based technologies — to meet medical necessity criteria. The current clinical evidence does not support their use as adjunctive tests for oral cancer detection.
The established standard of care, according to MM 0372, is a conventional visual and tactile examination using normal incandescent lighting. A thorough clinical exam followed by scalpel biopsy and microscopic evaluation remains the only pathway Cigna recognizes for final diagnosis and treatment planning. No adjunctive screening device changes that standard.
This is not a nuanced coverage position with carve-outs for high-risk patients or specific clinical scenarios. Cigna does not cover these systems, period. If your billing team has been exploring whether certain patient profiles — heavy tobacco users, patients with prior oral lesions — might qualify these services under medical necessity, the answer from MM 0372 is no.
There is no prior authorization pathway for adjunctive oral cancer screening systems under this policy. You cannot get prior auth approved for a service Cigna categorizes as experimental and investigational. Attempting prior authorization for CPT 41599 in this context will not result in coverage — it will result in a denial and wasted administrative time.
Cigna Oral Cancer Screening Exclusions and Non-Covered Indications
The full scope of this policy covers all adjunctive oral cancer screening systems proposed as supplemental detection tools. That includes every technology marketed for this purpose — fluorescence visualization devices, chemiluminescence rinse systems, tissue reflectance devices, and any similar emerging technology.
CPT 41599, described as "unlisted procedure, tongue, floor of mouth," is the code practices typically use to bill these services to medical insurers. Under MM 0372, Cigna classifies CPT 41599 when used for adjunctive oral cancer screening as experimental, investigational, and unproven. Those three words carry specific meaning in payer policy: no coverage, no exceptions, no appeals based on clinical literature unless Cigna formally revises its evidence review.
The real issue here is that "experimental and investigational" designations are notoriously hard to overturn through individual claim appeals. You would need a formal policy reconsideration supported by new peer-reviewed evidence, not a single-patient medical necessity letter. If you've been fighting these denials one claim at a time, you're using the wrong strategy.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Adjunctive oral cancer screening using fluorescence, chemiluminescence, or tissue reflectance systems | Not Covered — Experimental/Investigational/Unproven | CPT 41599 | No prior authorization available; no medical necessity pathway exists under current policy |
| Conventional visual and tactile oral examination (standard of care) | Covered under applicable E&M or procedure codes | Applicable E&M codes per clinical context | Not addressed by MM 0372 directly; covered under standard examination benefit |
| Scalpel biopsy and microscopic evaluation (standard of care) | Covered under applicable procedure codes | Applicable biopsy codes per clinical context | Recognized by Cigna as the appropriate diagnostic pathway for oral cancer |
Cigna Oral Cancer Screening Billing Guidelines and Action Items 2025
The effective date is September 26, 2025. If you haven't already made the following changes, do them now.
| # | Action Item |
|---|---|
| 1 | Pull CPT 41599 from your Cigna charge capture for adjunctive oral screening services. Any charge master entry or superbill line that ties CPT 41599 to VELscope, ViziLite, or similar technologies should be flagged. Submitting these claims to Cigna generates denials and appeals costs that exceed any potential reimbursement even if the denial were somehow overturned. |
| 2 | Audit claims submitted to Cigna under CPT 41599 from the past 12 months. If your team has been billing these services, identify any open claims or recent denials tied to adjunctive oral cancer screening billing. Don't spend resources appealing on medical necessity grounds — the policy explicitly forecloses that argument. |
| 3 | Review your patient financial responsibility disclosures. If you offer adjunctive oral cancer screening as a service, patients need to know before the appointment that Cigna will not cover it. Document their acknowledgment of financial responsibility. Billing these services directly to patients is possible — but only with proper advance notice and consent documentation in place. |
| 4 | Check your other payer contracts before assuming this is a Cigna-only issue. Many commercial payers take similar positions on adjunctive oral cancer screening systems. If you're billing CPT 41599 for these services across multiple payers, verify each payer's coverage position separately. This is not a universal Cigna problem — it's an industry-wide evidence gap that most payers have responded to similarly. |
| 5 | Talk to your compliance officer before September 26, 2025 if you have active Cigna contracts with any provision tied to experimental services. Some contracts include specific language about billing for experimental and investigational services — including what disclosures are required to patients and whether billing the patient directly is permissible. Your compliance officer needs to review your specific contract language, not just this policy summary. |
| 6 | Do not use unlisted procedure codes to repackage these services. CPT 41599 is already an unlisted code. Some practices try alternative unlisted codes when a primary approach is denied. That approach won't work here, and it creates compliance risk. If Cigna has designated the service as experimental, the code doesn't change the coverage determination. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Oral Cancer Screening Under MM 0372
The policy data for MM 0372 includes one code. The following tables reflect only the codes documented in the Cigna policy. No additional codes are inferred or added.
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 41599 | CPT | Unlisted procedure, tongue, floor of mouth | Considered Experimental/Investigational/Unproven when used for adjunctive oral cancer screening |
No covered CPT codes are listed in MM 0372. The policy does not designate any adjunctive oral cancer screening service as covered. The standard-of-care services Cigna recognizes — conventional examination, biopsy, microscopic evaluation — are governed by separate policies and standard procedure codes, not by MM 0372.
No ICD-10-CM diagnosis codes are listed in MM 0372. The policy does not specify diagnosis codes that would qualify or disqualify coverage. The experimental designation applies regardless of the diagnosis code submitted with CPT 41599 for these services.
What the Single-Code Policy Tells You
A one-code policy with a blanket experimental designation is about as clear as payer policy gets. There is no coverage matrix to work through. There are no criteria that, if met, would result in reimbursement. MM 0372 exists to document Cigna Healthcare's position that adjunctive oral cancer screening systems do not clear the evidence bar for coverage — and to give your billing team the unambiguous answer when a claim question comes up.
This is similar to how major payers handled genetic testing adjuncts in the early 2010s before evidence accumulated. The pattern is the same: a class of technology gets marketed to providers, practices start billing, payers formalize their non-coverage position, and billing teams get left holding denial paperwork. Oral cancer screening systems are in that cycle right now.
Get the Full Picture for CPT 41599
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.